{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:51:19Z","timestamp":1789588279250,"version":"build-2803163510"},"reference-count":39,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.3892\/ijo.2015.3314","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T11:02:15Z","timestamp":1451386935000},"page":"953-964","source":"Crossref","is-referenced-by-count":31,"title":["Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy"],"prefix":"10.3892","volume":"48","author":[{"given":"ROMANA","family":"MIKY\u0160KOV\u00c1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IVAN","family":"\u0160T\u011aP\u00c1NEK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARIE","family":"INDROV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JANA","family":"BIEBLOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JANA","family":"\u0160\u00cdMOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IVA","family":"TRUXOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IRENA","family":"MOSEROV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JITKA","family":"FU\u010c\u00cdKOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JI\u0158INA","family":"BART\u016e\u0147KOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RADEK","family":"\u0160P\u00cd\u0160EK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MILAN","family":"REINI\u0160","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,12,29]]},"reference":[{"key":"key20180107185043_b1-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00262-008-0531-4","article-title":"Combined modality immunotherapy and chemotherapy: A new perspective","volume":"57","author":"Ramakrishnan","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"key20180107185043_b2-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.addr.2006.04.002","article-title":"Combined chemoimmunotherapy of solid tumours: Improving vaccines?","volume":"58","author":"Nowak","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"key20180107185043_b3-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"key20180107185043_b4-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20180107185043_b5-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4161\/onci.21494","article-title":"Trial watch: Dendritic cell-based interventions for cancer therapy","volume":"1","author":"Galluzzi","year":"2012","journal-title":"Oncoimmunology"},{"key":"key20180107185043_b6-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"18192","DOI":"10.18632\/oncotarget.4145","article-title":"Phase I\/II clinical trial of dendritic-cell based immunotherapy (DCVAC\/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer","volume":"6","author":"Podrazil","year":"2015","journal-title":"Oncotarget"},{"key":"key20180107185043_b7-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human tumor cells killed by anthracyclines induce a tumor-specific immune response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res"},{"key":"key20180107185043_b8-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: The immunogenic effects of platinum-based chemo-therapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20180107185043_b9-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"key20180107185043_b10-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"e26536","DOI":"10.4161\/onci.26536","article-title":"Immunogenic cell death in radiation therapy","volume":"2","author":"Galluzzi","year":"2013","journal-title":"Oncoimmunology"},{"key":"key20180107185043_b11-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1749-6632.2010.05743.x","article-title":"Ex vivo- and in vivo-induced dead tumor cells as modulators of antitumor responses","volume":"1209","author":"Weiss","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"key20180107185043_b12-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00262-013-1474-y","article-title":"Antitumor immune responses induced by ionizing irradiation and further immune stimulation","volume":"63","author":"Frey","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"key20180107185043_b13-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/ijc.28766","article-title":"High hydrostatic pressure induces immunogenic cell death in human tumor cells","volume":"135","author":"Fucikova","year":"2014","journal-title":"Int J Cancer"},{"key":"key20180107185043_b14-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/PPO.0b013e3181eb5066","article-title":"Chemoimmunotherapy","volume":"16","author":"Emens","year":"2010","journal-title":"Cancer J"},{"key":"key20180107185043_b15-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00262-008-0505-6","article-title":"Cancer chemotherapy: Not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity","volume":"57","author":"M\u00e9nard","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"key20180107185043_b16-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clgc.2015.01.008","article-title":"New treatment options for patients with metastatic prostate cancer: What is the optimal sequence?","volume":"13","author":"van Dodewaard-de Jong","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"key20180107185043_b17-ijo-48-03-0953","first-page":"3689","article-title":"Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte\/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2\/neu tolerized mice","volume":"61","author":"Machiels","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107185043_b18-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1158\/1078-0432.CCR-09-1861","article-title":"A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice","volume":"15","author":"Malvicini","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107185043_b19-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"key20180107185043_b20-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"key20180107185043_b21-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180107185043_b22-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3892\/ijo.25.4.1165","article-title":"HPV16-associated tumours: Therapy of surgical minimal residual disease with dendritic cell-based vaccines","volume":"25","author":"Reinis","year":"2004","journal-title":"Int J Oncol"},{"key":"key20180107185043_b23-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3892\/ijo_00000528","article-title":"Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines","volume":"36","author":"Reinis","year":"2010","journal-title":"Int J Oncol"},{"key":"key20180107185043_b24-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"184","DOI":"10.14712\/fb2004050060184","article-title":"Immunogenicity of dendritic cell-based HPV16 E6\/E7 peptide vaccines: CTL activation and protective effects","volume":"50","author":"Indrov\u00e1","year":"2004","journal-title":"Folia Biol (Praha)"},{"key":"key20180107185043_b25-ijo-48-03-0953","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin","year":"1996","journal-title":"Cancer Res"},{"key":"key20180107185043_b26-ijo-48-03-0953","first-page":"3325","article-title":"Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model","volume":"57","author":"Foster","year":"1997","journal-title":"Cancer Res"},{"key":"key20180107185043_b27-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","article-title":"An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow","volume":"223","author":"Lutz","year":"1999","journal-title":"J Immunol Methods"},{"key":"key20180107185043_b28-ijo-48-03-0953","first-page":"517","article-title":"Effects of 5-azacytidine and trichostatin A on dendritic cell maturation","volume":"25","author":"Stepanek","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"key":"key20180107185043_b29-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.4049\/jimmunol.160.3.1240","article-title":"CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B\/c-Rel","volume":"160","author":"Yi","year":"1998","journal-title":"J Immunol"},{"key":"key20180107185043_b30-ijo-48-03-0953","first-page":"1011","article-title":"Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours","volume":"30","author":"Reinis","year":"2007","journal-title":"Int J Oncol"},{"key":"key20180107185043_b31-ijo-48-03-0953","first-page":"281","article-title":"NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours","volume":"25","author":"Indrov\u00e1","year":"2011","journal-title":"Oncol Rep"},{"key":"key20180107185043_b32-ijo-48-03-0953","first-page":"13","article-title":"Kinetics and function of peritoneal-exudate cells during local IL-2 gene-therapy of cancer","volume":"4","author":"Bubenik","year":"1994","journal-title":"Int J Oncol"},{"key":"key20180107185043_b33-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"217","DOI":"10.14712\/fb2003049060217","article-title":"Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: Cytolytic activity of spleen cells from tumour regressors","volume":"49","author":"Indrov\u00e1","year":"2003","journal-title":"Folia Biol (Praha)"},{"key":"key20180107185043_b34-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.2174\/092986708785909166","article-title":"Cells under pressure - treatment of eukaryotic cells with high hydrostatic pressure, from physiologic aspects to pressure induced cell death","volume":"15","author":"Frey","year":"2008","journal-title":"Curr Med Chem"},{"key":"key20180107185043_b35-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"e968434","DOI":"10.4161\/21624011.2014.968434","article-title":"Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy","volume":"3","author":"Adkins","year":"2014","journal-title":"Oncoimmunology"},{"key":"key20180107185043_b36-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.vaccine.2010.03.007","article-title":"IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer","volume":"28","author":"Martini","year":"2010","journal-title":"Vaccine"},{"key":"key20180107185043_b37-ijo-48-03-0953","first-page":"9","article-title":"Toll-like receptor signaling in anti-cancer immunity","volume":"50","author":"Okamoto","year":"2003","journal-title":"J Med Invest"},{"key":"key20180107185043_b38-ijo-48-03-0953","first-page":"1247","article-title":"CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours","volume":"30","author":"Reinis","year":"2007","journal-title":"Int J Oncol"},{"key":"key20180107185043_b39-ijo-48-03-0953","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4049\/jimmunol.1000060","article-title":"Generation of Th1-polarizing dendritic cells using the TLR7\/8 agonist CL075","volume":"185","author":"Spranger","year":"2010","journal-title":"J Immunol"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2015.3314\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T23:28:22Z","timestamp":1748734102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2015.3314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,29]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,12,29]]},"published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.3892\/ijo.2015.3314"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2015.3314","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,29]]}}}